Rigel PharmaceuticalsRIGL.OValuation Analysis

As of Oct 16, 2026, Rigel Pharmaceuticals (RIGL.O) trades at a P/E of 2.66x, P/B of 2.02x, P/S of 3.10x, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E sits at the 33rd percentile over the trailing 10Y window (vs. 33rd percentile over 3Y); P/B sits at the 7th percentile over the trailing 10Y window (vs. 31st percentile over 3Y); P/S sits at the 48th percentile over the trailing 10Y window (vs. 94th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 3rd percentile within its industry and the 3rd percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.00%; its historical percentile over the trailing long-term window is still accumulating data.
Notably, P/E and P/B aren't telling quite the same story, 26.0 points apart — worth checking the full percentile matrix on this page for the complete picture. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Rigel Pharmaceuticals operates in the Manufacturing sector. Data refreshes weekly and is for reference only, not investment advice.